Details
Stereochemistry | ACHIRAL |
Molecular Formula | C4H6N4O3S2 |
Molecular Weight | 222.245 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(=O)NC1=NN=C(S1)S(N)(=O)=O
InChI
InChIKey=BZKPWHYZMXOIDC-UHFFFAOYSA-N
InChI=1S/C4H6N4O3S2/c1-2(9)6-3-7-8-4(12-3)13(5,10)11/h1H3,(H2,5,10,11)(H,6,7,9)
Molecular Formula | C4H6N4O3S2 |
Molecular Weight | 222.245 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Approval Year
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:03:30 UTC 2023
by
admin
on
Fri Dec 15 15:03:30 UTC 2023
|
Record UNII |
O3FX965V0I
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QS01EC01
Created by
admin on Fri Dec 15 15:03:30 UTC 2023 , Edited by admin on Fri Dec 15 15:03:30 UTC 2023
|
||
|
NCI_THESAURUS |
C448
Created by
admin on Fri Dec 15 15:03:30 UTC 2023 , Edited by admin on Fri Dec 15 15:03:30 UTC 2023
|
||
|
NDF-RT |
N0000175517
Created by
admin on Fri Dec 15 15:03:30 UTC 2023 , Edited by admin on Fri Dec 15 15:03:30 UTC 2023
|
||
|
CFR |
21 CFR 522.44
Created by
admin on Fri Dec 15 15:03:30 UTC 2023 , Edited by admin on Fri Dec 15 15:03:30 UTC 2023
|
||
|
NCI_THESAURUS |
C29577
Created by
admin on Fri Dec 15 15:03:30 UTC 2023 , Edited by admin on Fri Dec 15 15:03:30 UTC 2023
|
||
|
WHO-ATC |
S01EC01
Created by
admin on Fri Dec 15 15:03:30 UTC 2023 , Edited by admin on Fri Dec 15 15:03:30 UTC 2023
|
||
|
NDF-RT |
N0000000235
Created by
admin on Fri Dec 15 15:03:30 UTC 2023 , Edited by admin on Fri Dec 15 15:03:30 UTC 2023
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
21.4
Created by
admin on Fri Dec 15 15:03:30 UTC 2023 , Edited by admin on Fri Dec 15 15:03:30 UTC 2023
|
||
|
CFR |
21 CFR 520.28
Created by
admin on Fri Dec 15 15:03:30 UTC 2023 , Edited by admin on Fri Dec 15 15:03:30 UTC 2023
|
||
|
LIVERTOX |
NBK548664
Created by
admin on Fri Dec 15 15:03:30 UTC 2023 , Edited by admin on Fri Dec 15 15:03:30 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
145177
Created by
admin on Fri Dec 15 15:03:30 UTC 2023 , Edited by admin on Fri Dec 15 15:03:30 UTC 2023
|
PRIMARY | |||
|
50634
Created by
admin on Fri Dec 15 15:03:30 UTC 2023 , Edited by admin on Fri Dec 15 15:03:30 UTC 2023
|
PRIMARY | |||
|
Acetazolamide
Created by
admin on Fri Dec 15 15:03:30 UTC 2023 , Edited by admin on Fri Dec 15 15:03:30 UTC 2023
|
PRIMARY | |||
|
481
Created by
admin on Fri Dec 15 15:03:30 UTC 2023 , Edited by admin on Fri Dec 15 15:03:30 UTC 2023
|
PRIMARY | |||
|
m1322
Created by
admin on Fri Dec 15 15:03:30 UTC 2023 , Edited by admin on Fri Dec 15 15:03:30 UTC 2023
|
PRIMARY | Merck Index | ||
|
CHEMBL20
Created by
admin on Fri Dec 15 15:03:30 UTC 2023 , Edited by admin on Fri Dec 15 15:03:30 UTC 2023
|
PRIMARY | |||
|
O3FX965V0I
Created by
admin on Fri Dec 15 15:03:30 UTC 2023 , Edited by admin on Fri Dec 15 15:03:30 UTC 2023
|
PRIMARY | |||
|
31163
Created by
admin on Fri Dec 15 15:03:30 UTC 2023 , Edited by admin on Fri Dec 15 15:03:30 UTC 2023
|
PRIMARY | |||
|
SUB05219MIG
Created by
admin on Fri Dec 15 15:03:30 UTC 2023 , Edited by admin on Fri Dec 15 15:03:30 UTC 2023
|
PRIMARY | |||
|
D000086
Created by
admin on Fri Dec 15 15:03:30 UTC 2023 , Edited by admin on Fri Dec 15 15:03:30 UTC 2023
|
PRIMARY | |||
|
ACETAZOLAMIDE
Created by
admin on Fri Dec 15 15:03:30 UTC 2023 , Edited by admin on Fri Dec 15 15:03:30 UTC 2023
|
PRIMARY | |||
|
59-66-5
Created by
admin on Fri Dec 15 15:03:30 UTC 2023 , Edited by admin on Fri Dec 15 15:03:30 UTC 2023
|
PRIMARY | |||
|
27690
Created by
admin on Fri Dec 15 15:03:30 UTC 2023 , Edited by admin on Fri Dec 15 15:03:30 UTC 2023
|
PRIMARY | |||
|
O3FX965V0I
Created by
admin on Fri Dec 15 15:03:30 UTC 2023 , Edited by admin on Fri Dec 15 15:03:30 UTC 2023
|
PRIMARY | |||
|
3002
Created by
admin on Fri Dec 15 15:03:30 UTC 2023 , Edited by admin on Fri Dec 15 15:03:30 UTC 2023
|
PRIMARY | |||
|
1986
Created by
admin on Fri Dec 15 15:03:30 UTC 2023 , Edited by admin on Fri Dec 15 15:03:30 UTC 2023
|
PRIMARY | |||
|
100000092652
Created by
admin on Fri Dec 15 15:03:30 UTC 2023 , Edited by admin on Fri Dec 15 15:03:30 UTC 2023
|
PRIMARY | |||
|
ACETAZOLAMIDE
Created by
admin on Fri Dec 15 15:03:30 UTC 2023 , Edited by admin on Fri Dec 15 15:03:30 UTC 2023
|
PRIMARY | Description: A white, or almost white, crystalline powder; odourless. Solubility: Very slightly soluble in water; slightly soluble in ethanol (~750 g/l) TS; practically insoluble in ether R. Category: Carbonic anhydrase inhibitor. Storage: Acetazolamide should be kept in a well-closed container. Definition: Acetazolamide contains not less than 99.0% and not more than 101.0% of C4H6N4O3S2, calculated with reference to the dried substance. | ||
|
DTXSID7022544
Created by
admin on Fri Dec 15 15:03:30 UTC 2023 , Edited by admin on Fri Dec 15 15:03:30 UTC 2023
|
PRIMARY | |||
|
200-440-5
Created by
admin on Fri Dec 15 15:03:30 UTC 2023 , Edited by admin on Fri Dec 15 15:03:30 UTC 2023
|
PRIMARY | |||
|
C28809
Created by
admin on Fri Dec 15 15:03:30 UTC 2023 , Edited by admin on Fri Dec 15 15:03:30 UTC 2023
|
PRIMARY | |||
|
DB00819
Created by
admin on Fri Dec 15 15:03:30 UTC 2023 , Edited by admin on Fri Dec 15 15:03:30 UTC 2023
|
PRIMARY | |||
|
56
Created by
admin on Fri Dec 15 15:03:30 UTC 2023 , Edited by admin on Fri Dec 15 15:03:30 UTC 2023
|
PRIMARY | |||
|
1005004
Created by
admin on Fri Dec 15 15:03:30 UTC 2023 , Edited by admin on Fri Dec 15 15:03:30 UTC 2023
|
PRIMARY | |||
|
6792
Created by
admin on Fri Dec 15 15:03:30 UTC 2023 , Edited by admin on Fri Dec 15 15:03:30 UTC 2023
|
PRIMARY | |||
|
167
Created by
admin on Fri Dec 15 15:03:30 UTC 2023 , Edited by admin on Fri Dec 15 15:03:30 UTC 2023
|
PRIMARY | RxNorm |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> INHIBITOR |
Ki
|
||
|
TARGET -> INHIBITOR |
Ki
|
||
|
TRANSPORTER -> INHIBITOR | |||
|
TRANSPORTER -> INHIBITOR | |||
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (TITRATION)
EP
|
||
|
TARGET -> INHIBITOR |
Ki
|
||
|
SALT/SOLVATE -> PARENT | |||
|
TARGET -> INHIBITOR |
Ki
|
||
|
TARGET -> INHIBITOR |
Ki
|
||
|
TARGET -> INHIBITOR |
Ki
|
||
|
TRANSPORTER -> INHIBITOR | |||
|
BINDER->LIGAND |
BINDING
|
||
|
SALT/SOLVATE -> PARENT | |||
|
TARGET -> INHIBITOR |
Ki
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
UNSPECIFIED IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Volume of Distribution | PHARMACOKINETIC |
|
|
|||
Biological Half-life | PHARMACOKINETIC |
|
|
|||